Microbial CRDMO For IVT Process Development: Complete Guide

The Growing Demand for IVT Process Development in mRNA Manufacturing

As mRNA-based therapeutics and vaccines continue to move through clinical and commercial pipelines, the in vitro transcription (IVT) step — the core enzymatic process that converts a DNA template into functional mRNA — has become a critical bottleneck for many developers. Biotech startups, universities, and biopharmaceutical companies alike are searching for partners who understand not just the chemistry of mRNA synthesis, but the full upstream and downstream ecosystem that supports it: template preparation, purification, formulation, and regulatory pathways to clinical use. This is precisely the space where a specialized microbial CRDMO (Contract Research, Development, and Manufacturing Organization) can make a measurable difference.

Why Microbial CRDMO Expertise Matters for mRNA and IVT Workflows

Yaohai Bio-Pharma, operating under the brand name Yaohai Bio-Pharma (full company name: Yaohai Bio-Pharmaceutical), has positioned itself as a microbial CRDMO specializing in microbial expression systems, with a dedicated nucleic acid drug development capability that directly supports IVT-based mRNA process development. Founded in 2010, the company has spent more than 16 years specializing in microbial expression systems, giving it a long-standing technical foundation that extends naturally into plasmid DNA production, mRNA synthesis, and RNA-based therapeutic development.

RNASUP mRNA Platform: Purpose-Built for Nucleic Acid Development

At the center of Yaohai Bio-Pharma’s nucleic acid offering is the RNASUP mRNA platform, a dedicated mRNA production platform designed to address mRNA production scale and stability challenges. This platform underpins the company’s nucleic acid drug development service line, which spans plasmid DNA template preparation and linearization, mRNA synthesis, modification, purification, and analytical characterization, circRNA research-grade sample preparation, lipid nanoparticle (LNP) formulation and delivery development, and process development and GMP manufacturing support for nucleic acid therapeutics.

Since 2022, Yaohai Bio-Pharma has supported over 800 RNA projects for universities and biotechs through this platform — a track record that speaks directly to the operational depth required to move IVT-derived mRNA from research-grade material to clinical-ready product.

From Plasmid DNA Template to mRNA Synthesis

A successful IVT process begins long before transcription itself — it begins with a high-purity, correctly linearized DNA template. Yaohai Bio-Pharma’s plasmid DNA capability includes GMP plasmid DNA production for viral vector construction and cell therapy applications, with high-purity pDNA supply positioned to meet downstream requirements, including those of mRNA template preparation. This upstream rigor is paired with the company’s microbial expression and strain engineering capabilities, which include strain construction, screening, optimization, and cell bank establishment, as well as expression platform development for recombinant proteins, nanobodies (VHHs), and plasmid DNA — all of which feed into a consistent, well-characterized nucleic acid production chain.

LNP Encapsulation: Completing the mRNA Delivery Chain

mRNA synthesized through IVT is only functional once it reaches its intended target, which is why delivery technology is treated as an integral part of Yaohai Bio-Pharma’s RNA platform rather than a separate service. The company’s LNP encapsulation technologies include SORT LNP and AbLNP, both engineered to address delivery challenges for mRNA therapeutics. By combining RNASUP mRNA production with these LNP formulation and delivery development capabilities, Yaohai Bio-Pharma offers a connected path from IVT-based synthesis through to a deliverable, formulated mRNA product — reducing the need for developers to coordinate multiple external vendors across the synthesis-to-delivery continuum.

Yaohai Bio-Pharma’s Integrated CRDMO Model

Yaohai Bio-Pharma describes itself as a microbial CRDMO specializing in microbial expression systems, providing a one-stop solution from R&D and process development to GMP manufacturing. For IVT and mRNA process development specifically, this means early-stage molecular design and construct development, strain and cell bank establishment where applicable, upstream and downstream process development, and research-grade material preparation can all be executed under a single service relationship, followed by process scale-up, CMC development, and eventually GMP drug substance and drug product manufacturing.

Proven Track Record Across RNA Projects

Quantified performance metrics support this integrated model. Yaohai Bio-Pharma reports a 98% technology transfer success rate, a 98% successful project delivery rate, and a 95% client retention rate — figures that reflect consistency across the company’s broader portfolio of 200+ successful projects, including 9 Phase III clinical projects, 15 Phase II clinical projects, and over 100 IND/Phase I projects, in addition to the 800+ RNA projects completed since 2022. For IVT and mRNA process development programs in particular, this data suggests a pattern of reliable technology transfer between development and manufacturing stages — a frequent point of failure in nucleic acid therapeutic programs industry-wide.

Regulatory and Quality Assurance Backbone

Nucleic acid therapeutic development does not succeed on process science alone; it requires facilities and quality systems capable of supporting global regulatory submission. Yaohai Bio-Pharma operates triple ISO-certified and EU QP-audited facilities, with 7,500L of total drug substance capacity spread across 5 production lines (ranging from 50L small scale to 2,000L large scale) and 2 drug product fill-finish lines. On the regulatory side, the company has a track record in US-China dual submissions and Australian filings, and its global regulatory affairs service supports IND/BLA submissions, European and Australian clinical trial registrations, and compliance across its core markets of the USA, China, Europe, and Australia.

Addressing Industry Pain Points Through Microbial Expression

Yaohai Bio-Pharma’s insight into industry pain points — including low yields and stability issues in mammalian expression systems, severe aggregation in scFv/Fab fragments, high biopharmaceutical manufacturing costs, and complex regulatory hurdles for US, China, and EU market entry — shapes how its nucleic acid services are delivered. Compared with generic mammalian platforms, the company’s microbial system specialization is positioned to reduce manufacturing overhead, and clients working with Yaohai Bio-Pharma report an average of 20% cost savings and 30% time savings relative to other CDMO companies.

Why Partner with Yaohai Bio-Pharma for IVT and mRNA Process Development

For organizations evaluating partners for IVT process development, the combination of a dedicated RNASUP mRNA platform, integrated LNP encapsulation through SORT LNP and AbLNP, GMP-ready plasmid DNA production, and a demonstrated history of 800+ RNA projects since 2022 positions Yaohai Bio-Pharma as a capable microbial CRDMO for this work. Its one-stop structure — spanning CMC process development, GMP manufacturing, quality control, and global regulatory affairs — along with its ISO certification, EU QP audit status, and documented 98% technology transfer and project delivery rates, offers biopharmaceutical companies, biotech startups, research institutes, and universities a structured, data-supported option for advancing mRNA programs from early IVT development through clinical and commercial supply.

http://www.yaohaibio-pharma.com
Yaohai Bio-Pharma